Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating reaffirmed by research analysts at Stifel Nicolaus in a report released on Wednesday. They presently have a $190.00 price target on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 30.26% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Mizuho dropped their target price on Jazz Pharmaceuticals PLC from $150.00 to $144.00 and set a “neutral” rating for the company in a report on Wednesday, May 31st. Cowen and Company reissued an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, May 10th. Deutsche Bank AG set a $178.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Monday, July 17th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $197.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $180.96.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down 0.17% during midday trading on Wednesday, reaching $145.61. 280,953 shares of the company traded hands. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75. The firm has a 50 day moving average of $152.07 and a 200-day moving average of $148.41. The stock has a market capitalization of $8.75 billion, a price-to-earnings ratio of 22.43 and a beta of 1.10.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The company had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. During the same period last year, the firm earned $2.67 earnings per share. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. Analysts forecast that Jazz Pharmaceuticals PLC will post $10.88 EPS for the current fiscal year.

WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/stifel-nicolaus-reiterates-buy-rating-for-jazz-pharmaceuticals-plc-jazz/1532359.html.

In other Jazz Pharmaceuticals PLC news, Director Paul L. Berns sold 662 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $142.37, for a total transaction of $94,248.94. Following the completion of the transaction, the director now owns 6,599 shares of the company’s stock, valued at $939,499.63. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Paul Treacy sold 1,304 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $143.32, for a total value of $186,889.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,917 shares of company stock valued at $1,973,227. Insiders own 4.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of JAZZ. Toronto Dominion Bank increased its position in shares of Jazz Pharmaceuticals PLC by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 81 shares during the last quarter. US Bancorp DE increased its position in shares of Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 368 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 295 shares during the last quarter. World Asset Management Inc acquired a new position in shares of Jazz Pharmaceuticals PLC during the first quarter valued at approximately $205,000. Finally, Gargoyle Investment Advisor L.L.C. acquired a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at approximately $206,000. 88.24% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.